Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approachesSonja Merkesdal, Jörg Ruof, Thomas Mittendorf, et al.
Health Economics Review|July 26, 2012
Measuring economic consequences of preterm birth - Methodological recommendations for the evaluation of personal burden on children and their caregiversJan-Marc Hodek, J-Matthias von der Schulenburg, Thomas Mittendorf
BMC Health Services Research|July 7, 2011
Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazineAnne Prenzler, Linnette Yen, Thomas Mittendorf, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 23, 2010
Health care costs and their predictors of inflammatory bowel diseases in GermanyAnne Prenzler, Bernd Bokemeyer, J-Matthias von der Schulenburg, et al.
Herz|January 22, 2009
[Comparative cost analysis of outpatient and inpatient rehabilitation for cardiac diseases]Jan Zeidler, Thomas Mittendorf, Gunda Vahldiek, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 24, 2009
[Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke]Christa Claes, Thomas Mittendorf, Martin Grond, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 22, 2007
Methods for determining cost-benefit ratios for pharmaceuticals in GermanyJ- Matthias Graf von der Schulenburg, Christoph Vauth, Thomas Mittendorf, et al.
GMS Health Technology Assessment|November 6, 2014
Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology AssessmentFrank Andersohn, Reinhard Bornemann, Oliver Damm, et al.
Health Policy (Amsterdam, Netherlands)|March 7, 2002
Diffusion of innovations: treatment of Alzheimer's disease in GermanyJörg Ruof, Thomas Mittendorf, Olaf Pirk, et al.
Health Economics Review|July 26, 2015
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in GermanySarah Neubauer, Mary Cifaldi, Thomas Mittendorf, et al.
Pageof 5